DXCM · Investment summary · as of 29 July 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
At $75.14, DXCM requires a 0% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 0%.
The value rests on an exit multiple of 17.0x and a terminal operating margin of 27%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause: CMS declines or indefinitely defers type-2 non-insulin coverage while Abbott prices the 15-day transition away.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Profitable GAAP every year since 2019 (8 consecutive); TTM GAAP operating margin 21.45%, an all-time high. |
| What do we forecast? | Revenue growth of 0% demonstrated; a terminal operating margin of 27%; an exit multiple of 17.0x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +1.8 percentage points. |
| What is it worth? | Twelve-month target $96.00, +28% from the struck price. Scenario-weighted expected return net of costs +27.8%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 29 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Named cause: CMS declines or indefinitely defers type-2 non-insulin coverage while Abbott prices the 15-day transition away. DXCM's price requires a 15.24% reported revenue CAGR against 11–13% guided for FY2026 (see Valuation). The gap is closed almost entirely by the Medicare non-insulin population — *half* of the type-2 non-insulin opportunity by the company's own statement — and that decision has no date. If CMS defers past 2028 and Abbott responds to the 15-day launch on price, DXCM settles at 9–10% growth with gross margin capped near 63% rather than progressing to 66%. On 10% growth and
Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored
On approach to the $96.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Named cause: CMS declines or indefinitely defers type-2 non-insulin coverage while Abbott prices the 15-day transition away. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +1.8 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: named cause: CMS declines or indefinitely defers type-2 non-insulin coverage while Abbott prices the 15-day transition away. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $66.12, which forces an immediate review.